For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

In February, The Wall Street Journal reported that Novartis CEO Vas Narasimhan was taking a highly selective approach toward potential acquisitions in the obesity treatment sector. The firm is ...

At Novartis, CEO Vas Narasimhan’s overall 2024 pay increased by 6.9% at grant value, reaching 14.2 million Swiss francs ($15.7 million), according to the company’s annual report (PDF).

CEO Vas Narasimhan pointed out during the Q4 2024 Earnings Call that if these yield positive results, Cosentyx would have further growth engines for the rest of this decade. Additionally ...

In response, Novartis CEO Vas Narasimhan, M.D., said, “We’ve had to give the appropriate level of adjustments on our rebates, but we've maintained [a] very good formulary position,” adding ...

Based in Bengaluru, Narasimhan as the Executive Committee member will lead their HR, Training & Knowledge Management (TKM), Corporate Services and Compliance teams. He will lead efforts in the ...

The company says it conducted a thorough evaluation of internal and external candidates, but decided that Vasant Narasimhan, known as Vas, was the best candidate to take the company forward.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Amazon's ambitious plan to disrupt the healthcare category seems to have had a course correction after the online retail giant announced it plans to shut down its telehealth service Amazon Care.

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in the coming months. The two ...